Toby Maher MD
Interstitial Lung Diseases
Professor of Clinical Medicine and Director of Interstitial Lung Disease
Join to View Full Profile
1520 San Pablo StSte 1000Los Angeles, CA 90033
Phone+1 323-442-5100
Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a pulmonologist specializing in the diagnosis and treatment of interstitial lung diseases including; idiopathic pulmonary fibrosis, sarcoidosis, lung disease related to connective tissue diseases and rheumatoid arthritis, chronic hypersensitivity pneumonitis, histiocytosis and LAM.
Education & Training
University of Southampton Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2020 - 2026
Clinical Trials
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Roles: Contact
- LYT-100 in Post-acute COVID-19 Respiratory Disease Start of enrollment: 2020 Dec 11
- Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Start of enrollment: 2022 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis.Toby Maher, Jin Woo Song, Mordechai Reuven Kramer, Lisa Lancaster, Tamera J Corte
BMJ Open Respiratory Research. 2025-05-22 - Nerandomilast in Patients with Progressive Pulmonary Fibrosis.Toby M Maher, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold
The New England Journal of Medicine. 2025-05-19 - Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.Luca Richeldi, Arata Azuma, Vincent Cottin, Michael Kreuter, Toby M Maher
The New England Journal of Medicine. 2025-05-18
Press Mentions
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF TrialMay 20th, 2025- Progressive Pulmonary Fibrosis Slows with Novel AgentMay 19th, 2025
- Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to PlaceboMay 19th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
